Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||0.62%||164.37||0.7%||$1382.14m|
|MRK||Merck & Co., Inc.||1.25%||73.18||0.7%||$1043.36m|
|BMY||Bristol-Myers Squibb Co.||0.81%||57.59||1.0%||$831.23m|
|LLY||Eli Lilly & Co.||-0.35%||244.25||1.1%||$718.99m|
|DRNA||Dicerna Pharmaceuticals, Inc.||-0.42%||38.00||0.3%||$157.34m|
|RPRX||Royalty Pharma Plc||1.58%||39.16||0.1%||$121.97m|
|NVO||Novo Nordisk A/S||2.96%||113.42||0.1%||$88.62m|
Biofrontera, Inc. is a biopharmaceutical company which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, in particular, diseases caused primarily by exposure to sunlight that result in sun damage to the skin. The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs; and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.